Enanta Pharmaceuticals | ENTA - Capital Ordinário





Capital Ordinário Alterar Data
AbbVie USD 1.77B 608K 2026-06
Amgen USD 541M 0 2026-09
Anika Therapeutics USD 13.89M 532K 2025-12
Arrowhead Research USD 141.14M 564K 2026-06
AstraZeneca USD 1.55B 28K 2026-09
BioCryst Pharmaceuticals USD 255.26M 42.2M 2026-06
Biogen USD 146.7M 200K 2025-09
Bristol-Myers Squibb USD 2.04B 7M 2026-06
Enanta Pharmaceuticals USD 212K 1000 2023-12
Gilead Sciences USD 1.24B 1000K 2026-06
GlaxoSmithKline GBP 2.02B 2.05B 2026-09
Halozyme Therapeutics USD 113.94M 106K 2026-09
Heron Therapeutics USD 188.31M 4.99M 2025-12
Immunic USD 120.38M 21.73M 2025-12
Incyte USD 200.98M 1.03M 2026-06
Insmed USD 218.28M 1.76M 2026-06
Ionis Pharmaceuticals USD 165.64M 265K 2026-06
J&J USD 2.41B 1.64M 2026-06
Karyopharm Therapeutics USD 22.54M 4.23M 2026-03
Ligand Pharmaceuticals USD 19.66M 19.64M 2025-09
Merck USD 2.47B 1.05M 2026-06
Neurocrine Biosciences USD 101.3M 750K 2026-09
Novartis USD 1.89B 12.09M 2026-09
Novavax USD 162.58M 106K 2025-12
Pfizer USD 5.7B 0 2026-06
PTC Therapeutics USD 83.33M 445K 2026-06
Roche Holding CHF 796.77M 1.15M 2026-06
Sarepta Therapeutics USD 107.23M 1.61M 2026-09
Vertex Pharmaceuticals USD 253.5M 200K 2026-09